Amicus Therapeutics (NASDAQ: FOLD) CEO reports option exercise and stock sale

Rhea-AI Filing Summary

Amicus Therapeutics' president and CEO, who also serves as a director, reported option exercises and share sales in the company’s stock. On December 15, 2025, the insider exercised 70,426 stock options at an exercise price of $9.03 per share, acquiring the same number of common shares. On the same date, the insider sold 77,926 shares of common stock at a weighted average price of $10.8566 per share, with individual sale prices ranging from $10.60 to $11.11.

After these transactions, the insider directly beneficially owned 1,129,782 shares of Amicus Therapeutics common stock and held no remaining derivative securities from this option grant. All of the options exercised were already fully vested and exercisable, and all reported trades were carried out under a Rule 10b5-1 trading plan adopted on September 13, 2024.

Insider Trade Summary

Net Seller: 77,926 shares ($846,011)

Net Sell 3 txns

Insider Campbell Bradley L

Role President and CEO

Sold 77,926 shs ($846K)

Type	Security	Shares	Price	Value
Exercise	Stock Options (right to buy)	70,426	$0.00	--
Exercise	Common Stock	70,426	$9.03	$636K
Sale	Common Stock	77,926	$10.8566	$846K

Holdings After Transaction: Stock Options (right to buy) — 0 shares (Direct); Common Stock — 1,207,708 shares (Direct)

Footnotes (1)

1. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.60 to $11.11 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. All of the options were fully vested and exercisable as of the transaction date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Campbell Bradley L

(Last) (First) (Middle)

47 HULFISH STREET

(Street)

PRINCETON NJ 08542

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS, INC. [ FOLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		M		70,426	A	$9.03	1,207,708	D
Common Stock	12/15/2025		S		77,926	D	$10.8566(1)	1,129,782	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$9.03	12/15/2025		M			70,426	(2)	01/04/2026	Common Stock	70,426	$0	0	D

Explanation of Responses:

1. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.60 to $11.11 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. All of the options were fully vested and exercisable as of the transaction date.

Remarks:

All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024.

	/s/ Christian Formica, Attorney-in-Fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transactions did Amicus Therapeutics (FOLD) report for December 15, 2025?

On December 15, 2025, Amicus Therapeutics’ president and CEO, who is also a director, exercised 70,426 stock options at $9.03 per share and sold 77,926 common shares at a weighted average price of $10.8566 per share.

How many Amicus Therapeutics (FOLD) shares does the reporting insider own after the latest transactions?

Following the reported option exercise and share sale on December 15, 2025, the insider beneficially owned 1,129,782 shares of Amicus Therapeutics common stock in direct ownership.

Were the Amicus Therapeutics (FOLD) insider transactions made under a Rule 10b5-1 plan?

Yes. The filing states that all transactions reported were effected under a Rule 10b5-1 trading plan that the reporting person adopted on September 13, 2024.

What stock option activity did the Amicus Therapeutics (FOLD) insider report?

The insider exercised 70,426 stock options (right to buy) with an exercise price of $9.03 per share. These options were fully vested and exercisable as of the transaction date, and 0 derivative securities from this grant remained afterward.

At what prices were the Amicus Therapeutics (FOLD) shares sold by the insider?

The reported sale of 77,926 shares was at a weighted average price of $10.8566 per share. The filing notes that individual sale prices ranged from $10.60 to $11.11 inclusive.

What roles does the reporting person hold at Amicus Therapeutics (FOLD)?

The reporting person is identified as both a director and an officer of Amicus Therapeutics, serving as the company’s President and CEO.